Moxonidin Actavis (Moxonidine)

Moxonidine works by selectively activating imidazoline I1 receptors in the brainstem. This activation dampens sympathetic outflow, leading to reduced peripheral vascular resistance, lower heart rate, and decreased renin release, all of which contribute to a fall in arterial blood pressure.

The specific dose of Moxonidin Actavis is determined by the prescribing healthcare professional based on the individual’s blood‑pressure profile, age, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of moxonidine in pregnancy or while breastfeeding has not been firmly established. Healthcare providers usually weigh the potential benefits against possible risks and may recommend alternative treatments if safer options are available.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moxonidine is a central imidazoline I1‑receptor agonist, differing from ACE inhibitors, ARBs, calcium‑channel blockers, and diuretics that act peripherally. It is particularly useful when sympathetic over‑activity contributes to hypertension or when patients need an additional agent to achieve control.

Moxonidin Actavis should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain stability and potency throughout the shelf life.

The medication is taken orally, usually with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water and avoid crushing or chewing unless specifically instructed.

Serious risks, though uncommon, include severe hypotension, bradycardia, allergic reactions such as rash or swelling, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, or signs of an allergic response.

Moxonidin Actavis is contraindicated in patients with known hypersensitivity to moxonidine or any excipients, and it should be used with caution in individuals with severe renal impairment, uncontrolled heart failure, or those taking interacting medications that could cause dangerous blood‑pressure drops.